Relationship of antibiotic treatment to recovery after acute FEV1 decline in children with cystic fibrosis

Annals of the American Thoracic Society

Volumn 14, Issue 6, 2017, Pages 937-942

  Morgan, Wayne J ^a   Wagener, Jeffrey S ^b   Pasta, David J ^c   Millar, Stefanie J ^c   Van Devanter, Donald R ^d   Konstan, Michael W ^d  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

^c ICON CLINICAL RESEARCH   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescent; Epidemiology; Respiratory function tests; Spirometry

Indexed keywords

ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CHILD; CHILD HOSPITALIZATION; CONVALESCENCE; COUGHING; CYSTIC FIBROSIS; DISEASE ASSOCIATION; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL CARE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; WHEEZING; ADOLESCENT; AMBULATORY CARE; CLINICAL TRIAL; COMPLICATION; DISEASE EXACERBATION; DRUG EFFECTS; LUNG; MULTICENTER STUDY; NORTH AMERICA; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; STATISTICAL MODEL;

ADOLESCENT; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LOGISTIC MODELS; LUNG; MALE; NORTH AMERICA; PROSPECTIVE STUDIES; PSEUDOMONAS INFECTIONS; QUINOLONES;

EID: 85020164695     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201608-615OC     Document Type: Article

References (18)

1. Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, Johnson CA, Konstan MW, Regelmann WE; Epidemiologic Study of Cystic Fibrosis. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004;37:400-406.
2. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-365.
3. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182: 627-632.
4. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, Johnson CA; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134-139.e1.
5. Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012;40:61-66.
6. Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW; Scientific Advisory Group, investigators; coordinators of the Epidemiologic Study of Cystic Fibrosis. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. J Pediatr 2013;163: 1152-1157.e2.
7. Konstan MW, Wagener JS, Vandevanter DR, Pasta DJ, Yegin A, Rasouliyan L, Morgan WJ. Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. J Cyst Fibros 2012;11:405-411.
8. Vandenbranden SL, McMullen A, Schechter MS, Pasta DJ, Michaelis RL, Konstan MW, Wagener JS, Morgan WJ, McColley SA; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatr Pulmonol 2012;47:135-143.
9. Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW; Scientific Advisory Group; Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis. Forced expiratory volume in 1 second variability helps identify patients with cystic fibrosis at risk of greater loss of lung function. J Pediatr 2016; 169:116-121.e2.
10. Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ Jr. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med 2010;182:1137-1143.
11. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-808.
12. Schechter MS, Wagener J, Konstan MW, Morgan W. Location and duration of treatment of cystic fibrosis respiratory exacerbations. Am J Respir Crit Care Med 2011;184:278-279.
13. Morgan WJ, Wagener J, Pasta DJ, Millar SJ, Konstan M. Antibiotics and hospitalization are associated with improved recovery after acute decline in FEV1 in patients with CF [abstract 444]. Pediatr Pulmonol 2014;49(Suppl 38):S377.
14. MorganWJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, Konstan MW, Light MJ, Rabin HR, Regelmann WE, et al. Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999;28:231-241.
15. Schechter MS, Regelmann WE, Sawicki GS, Rasouliyan L, VanDevanter DR, Rosenfeld M, Pasta D, Morgan W, Konstan MW. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: A comparison by care site. Pediatr Pulmonol 2014;50: 431-440.
16. Termoz A, Touzet S, Bourdy S, Decullier E, Bouveret L, Colin C, Nove-Josserand R, Reix P, Cracowski C, Pin I, et al. Effectiveness of home treatment for patients with cystic fibrosis: The intravenous administration of antibiotics to treat respiratory infections. Pediatr Pulmonol 2008;43:908-915.
17. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME; The Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642.
18. Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS. Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr 2009;155:634-639.e4.